MP20 Res'd PCT/PTO 08 FEB 2006

"Express Mail" mailing label number	EV 393129615 US
Date of Deposit February 8,	2006
I hereby certify that this paper or fee is be service under 37 C.F.R. 1.10 on the date i 22313-1450.	ndicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA
Queen Thomas	Gueen Thomas
Printed Name	Signature

<u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:

CLARK, Barry Peter

International

Serial No.:

PCT/US2004/022313

International

Application Date: August 9, 2004

US Nat'l Entry Date (if applicable):

For:

PYRIDINYLMORPHOLINE

DERIVATIVES

Docket No.:

X15987

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Docket No. X15987

International Serial No.: PCT/US2004/022313

MP20 Rec'd PCT/PTO 08 FEB 2006

Applicants respectfully request consideration of this information.

Respectfully submitted,

Charles E.Cohen, Ph.D.

Attorney for Applicants

Registration No. 34,565

Phone: 317-433-4983

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

6 Jebruary 2006

MP20 Rec'd PCTAPPO 08 FEB 2006

Sheet 1 of 1

FORM PTO 1449 (modified)			Atty. Docket No. X-15987 Atty. Docket No. International Seria No. 9 Int					39	
INFORMATION DISCLOSURE CITATION		First Applicant							
IN AN APPLICATION				CLARK, Barry Peter					
				Filing Date Group				•	
			US Nat'l Entry (if applicable)						
U.S. PA	ENT I	DOCUMENTS					•		
Examiner							olumns, Lines,		
Initials*	No. ¹	Number-Kind Code ² (if know	/n)	MM-DD-YYYY		Applicant of Cited Documen		Where Relevant Pages or Relevant Figures	
					· · · · · · · · · · · · · · · · · · ·			Appear	
	AA	US							
FOREIGN PATENT DOCUMENTS									
Examiner				Patentee or			T ⁶		
Initials*	No.1	Country Code ³ -Number ⁴ -	Publi	cation Date		nt of Cited ument		Pages, Columns, Lines, Where Relevant Passages or Relevant	
	ļ	Kind Code5 (if known)		DD-YYYY		Figures		ear	
	BA	WO 01/01973 A	01-11-2001						
	BB	WO 99/15177 A	04-01-1999						
	BC	GB 2 167 407 A	05-29-1986						
	BD	WO 00/39091 A	07-06-2000			·		·	
	BE	WO 04/017977 A	03-04-2004						
	BF	WO 04/018440 A	03-04-2004						
	BG	WO 03/106441 A	12-24-	2003		· · · ·			
	ВН	GB 2 060 622 A	05-07-	1981					
		NON PA	ATENT	LITERATU	JRE DOC	CUMENTS	6		
Examiner	Cite	Include name of the author							т6
Initials*	No. 1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher,						·	
	CA	CA International Search Report							
	CB	Thornber C.W., "Isosterism and Molecular Modification in Drug Design", Chemical							
		Society Reviews, Vol. 8, No. 4, 1979, pgs. 563-580							
						-			

Examiner	Date Consider	ered
Signature		
Signature		I

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Surden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.